Ended Therapeutic exploratory (Phase II) Facioscapulohumeral Muscular Dystrophy 1 (FSHD1)

Evaluation of Safety, Tolerability, and Changes in Biomarker and Clinical Outcome Assessments of Losmapimod for FSHD1 With Extension (FSHD)

EU CTIS ID: 2024-512736-29-00

What this study is testing

To evaluate the safety and tolerability of long-term dosing of losmapimod tablets in subjects with FSHD1

Therapeutic exploratory (Phase II)

A plain-language read of the study's public EU CTIS listing. The study team confirms the details.

Who can take part

You may be able to join if

1. FSHD1 subjects age 18-65 years.
10. Subject must complete the main study through the Week 60 visit in order to participate in the extension.
2. Subject will sign and date an informed consent form (ICF).
3. Subjects will have a confirmed diagnosis of FSHD1 with 1 to 9 repeats via assessment of the size of the D4Z4 array on chromosome 4 using the calculator provided by the sponsor. Genetic confirmation must be obtained prior to the screening MRI and baseline muscle biopsy; genetic confirmation can come from previous testing if verified with appropriate documentation. Due to stable transmission of repeat sizes within families, subjects with a clinical diagnosis of FSHD who have a first degree relative with a genetically confirmed diagnosis of FSHD1 may be entered into the study for screening and MRI. During screening, a confirmatory genetic diagnosis is conducted. If genetic testing during screening is necessary, the 4-week screening window will not start until the results are obtained and verified by the principal investigator.
4. Subject will be willing and able to comply with scheduled visits, treatment plan, study restrictions, laboratory tests, contraceptive guidelines, scheduled needle muscle biopsies, and other study procedures.
5. Male or female subjects: a. A female subject is eligible to participate if she is of non-childbearing potential defined as pre-menopausal females with a documented tubal ligation or hysterectomy; or postmenopausal defined as 12 months of spontaneous amenorrhoea or if of childbearing potential is using a highly effective method for avoidance of pregnancy (refer to Section 5.5) for the duration of the clinical trial and until 90 days following the last dose. The decision to include or exclude women of childbearing potential may be made at the discretion of the investigator and in accordance with local practice in relation to adequate contraception. b. Male subjects must agree to use one of the contraception methods listed in Section 5.5. This criterion must be followed from the time of the first dose of study medication until 90 days after the last study drug dose.

You likely can't join if

1. Subject has a history of any illness or any clinical condition that might confound the results of the study or pose an additional risk in administering study drug to the subject.
10. Vaccination with a live attenuated vaccine within 6 weeks of randomisation.
11. Subject has a history of alcohol, analgesic/opioid, and/or illicit drug abuse.
12. Subject has participated in a clinical trial in which they have received an investigational product 30 days prior to enrolment in the current study.
13. For subjects that are on drug(s) or supplements that may affect muscle function must be on a stable dose of that drug(s) or supplement for at least 3 months prior to enrolment in the study and remain on that stable dose.
14. Subject has a history of sensitivity to any of the study medications or components thereof, or a history of drug or other allergy that contraindicated their participation.

See the full eligibility criteria

Who can join

1. FSHD1 subjects age 18-65 years.
10. Subject must complete the main study through the Week 60 visit in order to participate in the extension.
2. Subject will sign and date an informed consent form (ICF).
3. Subjects will have a confirmed diagnosis of FSHD1 with 1 to 9 repeats via assessment of the size of the D4Z4 array on chromosome 4 using the calculator provided by the sponsor. Genetic confirmation must be obtained prior to the screening MRI and baseline muscle biopsy; genetic confirmation can come from previous testing if verified with appropriate documentation. Due to stable transmission of repeat sizes within families, subjects with a clinical diagnosis of FSHD who have a first degree relative with a genetically confirmed diagnosis of FSHD1 may be entered into the study for screening and MRI. During screening, a confirmatory genetic diagnosis is conducted. If genetic testing during screening is necessary, the 4-week screening window will not start until the results are obtained and verified by the principal investigator.
4. Subject will be willing and able to comply with scheduled visits, treatment plan, study restrictions, laboratory tests, contraceptive guidelines, scheduled needle muscle biopsies, and other study procedures.
5. Male or female subjects: a. A female subject is eligible to participate if she is of non-childbearing potential defined as pre-menopausal females with a documented tubal ligation or hysterectomy; or postmenopausal defined as 12 months of spontaneous amenorrhoea or if of childbearing potential is using a highly effective method for avoidance of pregnancy (refer to Section 5.5) for the duration of the clinical trial and until 90 days following the last dose. The decision to include or exclude women of childbearing potential may be made at the discretion of the investigator and in accordance with local practice in relation to adequate contraception. b. Male subjects must agree to use one of the contraception methods listed in Section 5.5. This criterion must be followed from the time of the first dose of study medication until 90 days after the last study drug dose.
6. Subject has a Clinical Severity Score between 2 and 4 on Ricci’s scale (scale range is from 0 to 5). Subjects that use a wheelchair or walker for any activity are not permitted to enroll in the study.
7. Subject commitment to complete the 2 visits for skeletal muscle needle biopsy and all visits for whole-body MRI.
8. Subject is able to complete the RWS, Timed Up and Go (TUG), and FSHD patientreported outcomes (PROs) (FSHD-RODS and FSHD-HI) at the screening visit.
9. Subject has an MRI-eligible muscle for biopsy as determined by the central reader.

What rules you out

1. Subject has a history of any illness or any clinical condition that might confound the results of the study or pose an additional risk in administering study drug to the subject.
10. Vaccination with a live attenuated vaccine within 6 weeks of randomisation.
11. Subject has a history of alcohol, analgesic/opioid, and/or illicit drug abuse.
12. Subject has participated in a clinical trial in which they have received an investigational product 30 days prior to enrolment in the current study.
13. For subjects that are on drug(s) or supplements that may affect muscle function must be on a stable dose of that drug(s) or supplement for at least 3 months prior to enrolment in the study and remain on that stable dose.
14. Subject has a history of sensitivity to any of the study medications or components thereof, or a history of drug or other allergy that contraindicated their participation.
15. Female subject is pregnant.
16. Female subject is lactating.
17. Subject is unwilling or unable to follow the procedures outlined in the protocol.
18. Subject has any contraindication for MRI (including severe claustrophobia and any shrapnel or metal implants in the body that are not MRI compatible).
19. Subject was mentally or legally incapacitated up to 2 years prior to enrolment.
2. Subject has a known or clinically suspected infection with human immunodeficiency virus or hepatitis B or C viruses.
20. Subject has abnormal laboratory results indicative of any significant medical disease That would preclude the subject’s participation in the study.
21. Subject, or close relative of the subject, is not a staff member directly involved with the conduct of the study at that site.
22. Subject has taken any anticoagulants for at least 1 month and anti-platelet agents for at least 1 week before each muscle biopsy.
3. Subject has current clinically significant liver or kidney dysfunction.
4. Subject screens positive for hepatitis B surface antigen, HCV antibody, or antibodies against HIV 1/HIV 2 antibodies.
5. Subject has any condition possibly affecting drug absorption,
6. Subject has a standard 12-lead ECG demonstrating QT interval by Fredericia (QTcF) >450 msec for male subjects and QTcF >470 msec for female subjects at Screening. If QTcF exceeds 450 msec for males or 470 msec for females.
7. Subject has a history of cardiac dysrhythmias requiring anti-arrhythmia treatment(s); or history or evidence of abnormal ECGs that would preclude the subject’s participation in the study.
8. Male subject has a female partner who is planning to become pregnant during the study or within 90 days after the last study drug dose.
9. Subject has donated blood (of approximately 1 pint [500 mL] or more) or has had any significant loss of blood within 90 days before the first study drug dose

The study team makes the final eligibility decision.

Questions & answers

Do participants get paid in this trial?

This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.

Is it free to join, and do I need insurance?

Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.

How long does this study last?

The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.

Who can join this trial?

This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.

Explore other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH)Heart failure Coronary artery disease

BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.